CATALYM
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
CATALYM
Industry:
Therapeutics
Founded:
2016-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.catalym.com
Total Employee:
11+
Status:
Active
Contact:
1844 66 34837
Total Funding:
59.33 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Board_member
2021-03-01
Current Employees Featured
Jörg Wischhusen Scientific Founder @ Catalym
Scientific Founder
Phil L’Huillier Managing Director and Chief Executive Officer (CEO) @ Catalym
Managing Director and Chief Executive Officer (CEO)
Christine Schuberth Wagner Chief Scientific Officer (CSO) @ Catalym
Chief Scientific Officer (CSO)
Anne Burger CFO @ Catalym
CFO
2018-01-01
Eugen Leo Chief Medical Officer (CMO) @ Catalym
Chief Medical Officer (CMO)
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Catalym
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Catalym
BioGeneration Ventures
BioGeneration Ventures investment in Series B - Catalym
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Catalym
coparion
coparion investment in Series B - Catalym
Wachstumsfonds Bayern
Wachstumsfonds Bayern investment in Series B - Catalym
Forbion Capital Partners
Forbion Capital Partners investment in Seed Round - Catalym
Official Site Inspections
http://www.catalym.com
- Host name: sh20024.ispgateway.de
- IP address: 92.205.54.255
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Catalym"
About CatalYm – Catalym
Anne Burger serves as Chief Financial Officer at CatalYm. She brings more than 15 years of experience in financial operations at biotech and medtech companies throughout Europe. She also served as the CFO and Co-Founder of Breath …See details»
CatalYm - Crunchbase Company Profile & Funding
CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a …See details»
Catalym 2025 Company Profile: Valuation, Funding & Investors
Catalym General Information Description. Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune systems. The company …See details»
CatalYm Announces Leadership Change – Catalym
Oct 11, 2024 CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as safe and efficacious immune therapy for solid tumors. GDF-15, an …See details»
CatalYm - Contacts, Employees, Board Members, Advisors & Alumni
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by AI . …See details»
CatalYm Company Profile - Office Locations, Competitors ... - Craft
CatalYm is a biopharmaceutical company developing cancer immunotherapies. It develops monoclonal antibodies that enhance the effective infiltration of immune cells into the …See details»
CatalYm GmbH - Innovations- und Gründerzentrum …
CatalYm is a spin-out of the Wurzburg University. The research group of Prof. Dr. Jörg Wischhusen has provided the most important results for the foundation of CatalYm. On that …See details»
CatalYm Company Information - Funding, Investors, and More
CatalYm shows strong potential with its focus on innovative immunotherapies for cancer patients. Based in Munich, it operates on a B2B model, supplying treatments to healthcare businesses. …See details»
CatalYm - Gilde Healthcare
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in difficult-to-treat cancer types. The company has identified GDF-15 as a key cancer therapy resistance …See details»
CatalYm - Brandon Capital
San Francisco. Brandon Capital LLC. 1 Letterman Ave, Suite C3-330. San Francisco, CA 94129. Phone +61 3 9657 0700. Email: info@brandoncapital.com.auSee details»
CatalYm - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Seed Round - CatalYm . 1: …See details»
Catalym - News, Articles, Whitepapers - Drug Target Review
Aug 24, 2023 3 April 2024 | By Dr Christine Schuberth-Wagner (CatalYm) Dr Christine Schuberth-Wagner serves as Chief Scientific Officer at CatalYm. She joined the company in …See details»
CatalYm cashes in on early-stage cancer data with $150M series D
Jul 16, 2024 CatalYm’s series D haul is close to triple their series C total in late 2022, when the biotech raised about $49 million. Visugromab targets growth differentiation factor 15, an …See details»
catalYm - Forbion
CatalYm is developing innovative immunotherapies targeting Growth Differentiation Factor 15 (GDF-15) to transform the tumor microenvironment and to substantially improve treatment …See details»
News & Events - Catalym
5 days ago Follow CatalYm’s journey and learn more about our most recent milestones. April 25, 2025. CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of …See details»
catalym.com Reviews: Is this site a scam or legit?
Catalym.com Review. The Scam Detector website Validator gives catalym.com a medium-risk trust score on the platform: 67.2.It signals that the business is best defined by the following …See details»
CatalYm to Present New Data Demonstrating GDF-15 Blockade …
4 days ago CatalYm GmbH info@catalym.com Media Inquiries Trophic Communications Dr. Stephanie May or Anja Heuer Phone: +49 171 185 56 82 or +49 151 106 199 05 …See details»
CatalYm Appoints Scott Clarke CEO as Company Initiates Global …
Jan 9, 2025 These events provide significant momentum for Scott’s start as CEO,” said Jon Edwards, Interim Chair of CatalYm’s Board of Directors. “We are confident that his experience …See details»
Science – Catalym
Aug 30, 2021 CatalYm and its collaborators have identified GDF-15 as a key regulator in cancer therapy resistance by unraveling the underlying pathways contributing to immune evasion, …See details»
Pipeline – Catalym
CatalYm has demonstrated that GDF-15 inhibits both the activation and relocation of important players of anti-tumoral immune responses (Nature Communications, 2023; Annals of …See details»